---
document_datetime: 2025-06-30 16:00:45
document_pages: 3
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/glyxambi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: glyxambi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.9532285
conversion_datetime: 2025-12-30 09:04:23.921157
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Glyxambi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Article 61(3) /     | -Notification acc. Article 61(3) - | 30/06/2025                          |                                          | PL                              |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | Update of the package leaflet with the addition of contactdetailsof local representatives.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |     |    | EMA/N/0000281785   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----|--------------------|
| Variation type II / EMA/VR/0000248932 | This was an application for a variation following a worksharing procedure according toArticle20of CommissionRegulation(EC) No 1234/2008. C.1.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation,including the risk management plan - C.1.11.b Implementation of change(s) which require to be further substantiatedbynewadditional datatobe submittedbytheMAHwheresignificant assessmentbythecompetentauthorityis required*-Accepted SubmissionofanupdatedRMPversion15.0 forTrajenta andJentadueto and updated RMPversion12.0for Glyxambi inorder to review thelistofsafety concerns inline with GVPModuleV,Rev2. | 05/06/2025 | N/A |    |                    |
| Article 61(3) / EMA/N/0000263596      | -Notification acc.Article 61(3)- Update of thelistoflocalrepresentatives in the package leaflet.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 01/04/2025 |     | PL |                    |

<div style=\"page-break-after: always\"></div>

| Variation typeIA_IN / EMA/VR/0000260241   | C.I.3Change(s)in theSummary ofProduct Characteristics,LabellingorPackageLeaflet of humanmedicinalproducts intended to implementtheoutcomeofaprocedure concermingPSURorPASS,orthe outcome of the assessmentdonebythe competent authority under Articles 45 or 46 of Regulation 1901/2006-C.1.3.a Implementationofwording agreedbythe competent authority - Accepted   | 25/03/2025   |     | SmPC   |
|-------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-----|--------|
| VariationtypeIA/ EMA/VR/0000249092        | A.ADMINISTRATIVECHANGES-A.7 Deletion ofmanufacturingsitesforanactive substance, intermediate or finished product, packaging site, manufacturer responsible for batchrelease,sitewherebatch controltakes place,or supplier of a startingmaterial, reagent or excipient(when mentioned in the dossier)* - Accepted                                                     | 11/03/2025   | N/A |        |